Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Regeneron Pharmaceuticals (Nasdaq: REGN) hit a new 52-week high Wednesday as it is currently trading at $221.97, above its previous 52-week high of $220.98 with 600,692 shares traded as of 10:20 a.m. ET. Average volume has been 786,900 shares over the past 30 days. Regeneron has a market cap of $20.55 billion and is part of the health care sector and drugs industry. Shares are up 26% year to date as of the close of trading on Tuesday. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 31.9, above the S&P 500 P/E ratio of 17.7.